Proposals of the Shareholders' Nomination Board of Terveystalo for the Annual General Meeting 2026

Terveystalo’s Shareholders' Nomination Board proposes a six-member Board for the AGM 2026 with re-elections of Kari Kauniskangas (recommended for re-election as Chairman), Sofia Hasselberg, Ari Lehtoranta and Teija Sarajärvi, and the election of two new members, Nathalie Ahlström and Petri Castrén; three incumbents (Carola Lemne, Kristian Pullola and Matts Rosenberg) will not stand for re-election. The Nomination Board proposes a moderate increase in board compensation: Chairman EUR 94,300; Vice-Chairman EUR 55,400; members EUR 44,300; Audit Committee Chair EUR 55,400, plus attendance fees (EUR 700 Finland / EUR 1,455 elsewhere in Europe / EUR 2,910 outside Europe; EUR 700 for electronic meetings). It also proposes that 40% of annual board remuneration be paid in company shares purchased on market (transaction costs and transfer tax reimbursed) and 60% in cash, with shares to be bought within two weeks after publication of the Q3 2026 result.

Analysis

Market structure: The Nomination Board’s proposals are governance-tidy rather than strategic shock—six board members, two new independents, and 40% of board pay in market-purchased shares create a small but visible incremental buy pressure (~€150k/year based on proposed fees) concentrated in a two-week window after the Q3 2026 report. Winners: existing shareholders (better alignment, modest float reduction) and long-term holders if governance refresh yields operational focus; losers: none material immediately (no dilution). Cross-asset impact is negligible—credit spreads and FX unlikely to move; equity-options micro-volatility may rise around the specific buy window.

Risk assessment: Tail risks include a regulatory reimbursement shock in Finland/Sweden (>=10-15% revenue impact), industrial action among healthcare staff, or a strategic pivot pushed by large institutional owners; each could compress multiples by 200–500bp. Time horizons: immediate (days) — essentially neutral; short-term (weeks–months) — watch AGM vote and any governance statements; long-term (quarters–years) — improved alignment could drive 50–150bp multiple expansion if execution follows. Hidden dependency: nomination board composition (large pension funds) signals willingness to steer strategy or pursue M&A; that increases probability of activism or sale processes within 12–24 months.

Trade implications: Direct play — establish a modest 1–2% long in Terveystalo (Nasdaq HEL: TTALO) on conviction of governance-led steadying, scale in on >10% pullbacks, target 15–30% upside over 6–12 months, stop 8–10%. Options — buy a November 2026 bull-call spread (buy ATM, sell +20–30% OTM) sized at 0.5% portfolio to capture the concentrated two-week share purchase window after Q3 2026 results; enter 4–6 weeks before expected Q3 release and exit within two weeks after. Hedge — if regulatory signals (public statements from Finnish Ministry of Social Affairs & Health or major union action) appear within 90 days, add protective puts covering 30–50% of position.

Contrarian angles: The market will likely underprice the signaling value of pension-fund-led board changes — not the share-purchase magnitude, but the increased chance of strategic consolidation or disciplined capital allocation (M&A or buybacks) within 12–24 months. Historical parallels: small governance-driven buy-ins rarely move price alone, but when combined with activist-capital on the nomination board they precede corporate actions ~20–30% of the time in Nordic midcaps. Unintended consequence: 40%-in-shares rule slightly tightens free float and concentrates trading around disclosure windows, creating short-term liquidity squeezes that can be exploited with options timing.

Key Decisions for Investors

• Establish a 1–2% long position in Terveystalo (Nasdaq HEL: TTALO) over the next 2–8 weeks; scale into any >10% pullback; set a 6–12 month target of +15–30% and a stop-loss of 8–10% to limit downside from regulatory shocks.
• Purchase a small Nov 2026 bull-call spread on TTALO (buy ATM, sell +20–30% OTM) sized to ~0.5% of portfolio value; enter 4–6 weeks before the expected Q3 2026 release and plan to close within two weeks after the publication to capture market purchase-induced bid.
• If holding >1% exposure, hedge 30–50% with puts (3–6 month tenor) if Finnish Ministry of Social Affairs & Health issues reimbursement guidance or if large healthcare union negotiations escalate within the next 90 days; otherwise avoid costly long-dated hedges.
• Monitor three triggers before increasing exposure: (1) AGM 2026 vote outcomes and any strategic statements within 30 days, (2) Q3 2026 publication date to prepare option timing (buy window begins the day after publication), and (3) any public commentary from Ilmarinen/Varma (nomination board members) on M&A or capital returns within 12 months.